CaviCide HP
- Hydrogen peroxide formulation
- 1 minute universal contact time against 70 listed pathogens
- No gloves needed
CaviCide HP surface disinfectant offers a 1 minute universal contact time against 71 listed pathogens. Meeting all levels of the EPA’s Emerging Viral Pathogen Claim (EPA List Q), CaviCide HP utilizes a hydrogen peroxide formulation.
Features and Benefits:
-
- Efficient Disinfection: 1 step cleaning/disinfection
- Broad Spectrum Efficacy: Effective disinfection against 71 pathogens including MDRO’s (Multidrug Resistant Organisms)
- Ease of Use: Ready-to-Use liquid requires no mixing or dilution, reducing the risk of errors, saving time and improving compliance
- Low Toxicity Level: US EPA Toxicity Category IV product – No gloves needed!
Qualifications:
-
- Meets all levels of the EPA’s rigorous Emerging Viral Pathogen Claim (EPA List Q)
CaviCide HP List of Uses:
-
- Ambulance equipment surfaces
- Animal care facilities
- Bathrooms
- Correctional facilities
- Daycare centers
- Dental offices
- Emergency medical settings
- Emergency vehicles
- Exterior surfaces of anesthesia machines and respiratory therapy equipment
- Health club facilities
- Hospitals
- Infant/child care equipment surfaces
- Interior and exterior surfaces of infant incubators, bassinets
- Isolation areas
- Laboratories
- Laundry rooms
- Neonatal units
- Nursing homes
- Operating rooms
- Ophthalmic and optometric facilities
- Outpatient surgical centers
- Oxygen hoods
- Schools
- Surgical centers
CaviCide HP Kill Claims:
Mycobacterium
-
- Mycobacterium tuberculosis var: bovis (BCG)
Viruses (Non-Enveloped)
-
- Human Norovirus
- Human Rotavirus
- Rhinovirus Type 37
- Rhinovirus Type 1A
- Human Adenovirus Type 5
- Enterovirus Type D68
Viruses (Enveloped)
-
- Herpes simplex virus Type 1 & Type 2
- Avian Influenza A virus (H7N9)
- Avian Influenza A virus (H5N1)
- Influenza A virus (H3N2)
- Influenza B virus (H1N1)
- Parainfluenza virus Type 3
- Hepatitis B virus (HBV)
- Human Hepatitis C virus (HCV)
- Human lmmunodeficiency virus Type 1 (HIV-1)
- Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2)
- Vaccinia virus
- SARS-Associated Coronavirus (SARs-CoV)
- Cytomegalovirus (CMV)
- Influenza A virus (H1N1) Strains A/4108/2009 and A/04/09
- Human Coronavirus
- Respiratory Syncytial Virus (RSV)
- Measles virus
Pathogenic Fungi
-
- Trichophyton interdigitale
- Candida auris
- Candida albicans
- Ketoconazole-resistant Candida albicans
Bacteria
-
- Pseudomonas aeruginosa
- Staphylococcus aureus
- Salmonella enterica
- Bordetella pertussis
- Enterococcus faecium
- Klebsiella aerogenes
- Klebsiella pneumoniae
- Escherichia coli
- Escherichia coli O157:H7
- Burkholderia cepacia
- Stenotrophomonas maltophilia
- Streptococcus pyogenes
- Listeria monocytogenes
- Shigella dysenteriae
- Serratia marcescens
- Bordetella bronchiseptica
- Campylobacter jejuni
- Proteus vulgaris
Multi-Drug-Resistant Bacteria (MDRO)
-
- Penicillin-Resistant Streptococcus pneumoniae (PRSP)
- Vancomycin-Resistant Enterococcus faecalis (VRE)
- Methicillin-Resistant Staphylococcus aureus (MRSA)
- Hospital-Acquired and Community Acquired Methicillin-Resistant
Staphylococcus aureus (HA-MRSA and CA-MRSA) - Vancomycin Intermediate Staphylococcus aureus (VISA)
- Vancomycin Resistant Staphylococcus aureus (VRSA)
- Linezolid-Resistant Staphylococcus aureus (LRSA)
- Carbapenem-Resistant Klebsiella pneumoniae
- Multidrug-Resistant Acinetobacter baumannii (MRAB) Strains
ATCC 19606 and ATCC BAA-1605 - NDM-1 Enterobacter cloacae
- NDM-1 Klebsiella pneumoniae
- MBL Pseudomonas aeruginosa
- NMD-1 Escherichia coli
- ESBL Klebsiella pneumoniae
- ESBL Escherichia coli
- Multidrug-Resistant Klebsiella pneumoniae
- Carbapenem-Resistant Escherichia coli
- Carbapenem-Resistant Enterobacter cloacae
- Methicillin-Resistant Staphylococcus epidermidis (MRSE)
- Multi-Drug Resistant Pseudomonas aeruginosa
